Business

SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders

SAN DIEGO & BOSTON, February 02, 2026--SEQSTER, the leading healthcare technology company and the data connection, collection, and orchestration layer for patient health data, and Praxis Precision Medicines, Inc., today announced the expansion of a successful partnership to accelerate clinical trials, data collection, and real-world evidence (RWE) generation across Praxis's clinical development programs.

articlePraxis Precision Medicines, Inc.February 2, 20263/company/praxis-precision-medicines-inc/news/seqster-announces-expanded-partnership-with-praxis-precision-medicines-to-accelerate-clinical-trials-in-cns-disorders
SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders

About this update from Praxis Precision Medicines, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/563868f0081a3579bf987dd5a29056cd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mLgAprQiPfEkjnBonQ2NWw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/563868f0081a3579bf987dd5a29056cd","width":480,"height":480}},"lazy":false},{"type":"text","content":"Multi-study collaboration leverages SEQSTER's real world data (RWD) platform to support Praxis's portfolio of precision therapies for CNS disorders","length":155,"tagName":"p","attribs":{}},{"type":"text","content":"SAN DIEGO & BOSTON, February 02, 2026--(BUSINESS WIRE)--SEQSTER, the leading healthcare technology company and the data connection, collection, and orchestration layer for patient health data, and Praxis Precision Medicines, Inc., today announced the expansion of a successful partnership to accelerate clinical trials, data collection, and real-world evidence (RWE) generation across Praxis's clinical development programs.","length":432,"tagName":"p"},{"type":"text","content":"Building on early success in Praxis’s innovative Essential3 Program for Essential Tremor, SEQSTER's platform continues to support the broader ENERGY program, Praxis's comprehensive program advancing vormatrigine for the treatment of epilepsy.","length":250,"tagName":"p"},{"type":"text","content":""At Praxis, we are committed to delivering life-altering treatments to patients with CNS disorders faster and more effectively than has ever been done before," said Megan Sniecinski, Chief Operating Officer, Praxis Precision Medicines. "SEQSTER has been a foundational element of our clinical trial execution, enabling more efficient trial enrollment while capturing the longitudinal real-world data we need to advance our programs. Our partnership represents a shared commitment to delivering better outcomes for patients and driving forward innovative ways to accelerate clinical research."","length":612,"tagName":"p"},{"type":"text","content":"SEQSTER's platform provides Praxis with automated access to patient-consented electronic health records from across the U.S. healthcare system, supporting patient screening, ...

More updates from Praxis Precision Medicines, Inc.

data collectionclinical trialsCNS disordershealth datadata connectionENERGY programelectronic health recordspatientsreal-world datahealthcare technology